Get the Stockscreener App
38.31
2.74%
-1.08
After Hours:
37.76
-0.55
-1.44%
Ascentage Pharma Group International Adr stock is traded at $38.31, with a volume of 2,316.
It is down -2.74% in the last 24 hours and up +3.12% over the past month.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
See More
Previous Close:
$39.39
Open:
$37.79
24h Volume:
2,316
Relative Volume:
0.14
Market Cap:
$3.34B
Revenue:
$136.33M
Net Income/Loss:
$-56.34M
P/E Ratio:
-51.05
EPS:
-0.7504
Net Cash Flow:
$-18.87M
1W Performance:
-0.80%
1M Performance:
+3.12%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$37.76
$38.31
1-Week Range:
$37.76
$41.38
52-Week Range:
$17.09
$43.58
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
Name
Ascentage Pharma Group International Adr
Sector
Industry
Phone
-
Address
-
Compare AAPG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
38.31 | 3.65B | 136.33M | -56.34M | -18.87M | -0.7504 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-25 | Initiated | JP Morgan | Overweight |
Ascentage Pharma Group International Adr Stock (AAPG) Latest News
Ascentage Pharma Completes Offshore Placement to Boost Global Operations - TipRanks
Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement - GlobeNewswire Inc.
McGraw Hill, Inc. Plans $500 Million IPO for July 24th (MH) - Defense World
Ascentage Pharma Group International – Unsponsored ADR’s (NASDAQ:AAPG) Lock-Up Period Set To End on July 23rd - Defense World
Gates Industrial (NYSE:GTES) Reaches New 1-Year High After Analyst Upgrade - Defense World
Accelerant Holdings (ARX) to Raise $551 Million in IPO - Defense World
Certara (NASDAQ:CERT) Trading Down 4.8% on Analyst Downgrade - Defense World
Diginex Stock Scheduled to Split on Friday, August 1st (NASDAQ:DGNX) - Defense World
Atalaya Mining (LON:ATYM) Sets New 12-Month High Following Analyst Upgrade - Defense World
Investors Buy Large Volume of Ramaco Resources Call Options (NASDAQ:METC) - Defense World
VerticalScope Holdings Inc. (TSE:FORA) Receives C$10.45 Consensus Price Target from Analysts - Defense World
Ascentage Pharma announces $192.3 million share placement By Investing.com - Investing.com South Africa
Ascentage Pharma announces $192.3 million share placement - Investing.com
Moser Wealth Advisors LLC Lowers Stake in NVIDIA Corporation (NASDAQ:NVDA) - Defense World
Ascentage Pharma Strengthens Leadership with Key Appointments - TipRanks
US Stocks Likely To Open Mixed As Trump Issues Tariff… - inkl
Ascentage Pharma’s Studies to be Featured at 2025 EHA Congress - TipRanks
Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress - marketscreener.com
Ascentage Pharma Unveils Promising Data on Alrizomadlin at ASCO 2025 - TipRanks
Ascentage Pharma Announces Successful AGM Resolutions on May 19, 2025 - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA) - The Globe and Mail
Is Ascentage Pharma (AAPG) the Best Performing Healthcare Stock to Buy Now? - Yahoo Finance
Ascentage Pharma Files Annual Report, Announces Shareholder Meeting By Investing.com - Investing.com South Africa
Ascentage Pharma Files Annual Report, Announces Shareholder Meeting - Investing.com
JPMorgan sets Ascentage Pharma stock to Overweight, $27 target - Investing.com
Takeda Pharmaceutical Company (TKPYY) Stock: Strategic Focus on Oncology and Growth Opportunities - Value the Markets
Ascentage Pharma to Announce 2024 Financial Results and Corporate Update - TipRanks
Avoid the Trap: 3 High-yield Dividend Stocks With Safe Payouts - The Globe and Mail
Ascentage Pharma IPO opens flat - Investing.com
Ascentage Pharma shares slide ahead of ADS debut on Nasdaq - Investing.com
Ascentage prices first biotech IPO of 2025, raising $126M - BioPharma Dive
Ascentage Pharma sets terms for $149 million US IPO - The Pharma Letter
Takeda-backed Ascentage Pharma files for $100M IPO (IPO:NYSEARCA) - Seeking Alpha
Market Capitalization: What It Is, Formula for Calculating It - Investopedia
Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares - PR Newswire
Takeda, Ascentage Pharma Sign Option Agreement - Contract Pharma
Top Biotech Stocks: Exploring Innovation Opportunities - MarketBeat
BIIB Stock Quote Price and Forecast - CNN
Capital Markets - Wilson Sonsini
Morningstar | Empowering Investor Success - Morningstar
ADVFN | Live Stock, Options & Crypto Market Data, Trading Tools & Community - ADVFN Logo
Ascentage Pharma Group International Adr Stock (AAPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.91%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):